Rigel Pharmaceuticals Inc. (RIGL)

Trade RIGL now with
3/6/2018 4:04:00 PM Rigel Pharmaceuticals Q4 Loss Per Share $0.18 Vs Loss $0.16 Last Year
3/1/2018 7:35:18 AM Rigel Reports 2 Fostamatinib Presentations At 4th Biennial Summit Of Thrombosis & Hemostasis Societies Of North America
1/4/2018 7:31:43 AM Rigel Pharma To Provide Business Review And Updated Phase 2 Results For Fostamatinib In AIHA
12/15/2017 7:31:38 AM Rigel Pharma Announces Resignation Of Ryan Maynard, EVP And CFO, Effective December 31, 2017
11/7/2017 4:04:33 PM Rigel Pharmaceuticals Q3 Loss/share $0.14 Vs. Loss $0.24 Year Ago
11/2/2017 7:32:48 AM Rigel Welcomes Gregg Lapointe To Board Of Directors
10/10/2017 4:02:36 PM Rigel Announces Closing Of Public Offering Of Common Stock
10/4/2017 10:38:45 PM Rigel Pharmaceuticals Prices Public Offering Of 18.10 Mln Shares At $3.35/shr
10/3/2017 4:02:59 PM Rigel Announces Proposed Public Offering Of Common Stock
10/3/2017 7:34:01 AM Fostamatinib Meets Pre-Specified Primary Endpoint In Stage 1 Of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study
10/2/2017 7:32:12 AM Rigel Pharma: FDA Says It Is Not Planning To Hold ODAC Meeting To Discuss NDA For Fostamatinib